Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2021 07:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.

AGOURA HILLS, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra...
March 08, 2021 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics,...
March 01, 2021 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS

AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
February 01, 2021 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™

AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
November 04, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT

AGOURA HILLS, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud...
October 23, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON ADVISOR DR. SUHAS KSHIRSAGAR WILL PRESENT AT DELHI UNIVERSITY ON ARTISHIELD™ FOR IMPROVING SYMPTOMS FOR COVID-19

Dr. Kshirsagar will speak on ARTIShield™ at Delhi University on Oct 28, 2020 in his talk titled “Ayurveda concepts of Pandemic and Immunity”Dr. Kshirsagar is advisor to Mateon on its Ayurvedic product...
October 19, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON’S PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA.

AGOURA HILLS, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Republica Argentina – Poder...
October 12, 2020 08:00 ET | Source: Mateon Therapeutics, Inc.

MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL

AGOURA HILLS, California, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced...
July 13, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.

Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...
June 10, 2020 08:00 ET | Source: Mateon Therapeutics

Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO

The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...